多囊卵巢综合征表型与妊娠及新生儿结局的相关性
该回顾性队列研究纳入PPCOS I和II随机对照试验的1376例参与者,比较高雄激素型(A和B)与非高雄激素型(D)多囊卵巢综合征(PCOS)表型的妊娠和新生儿结局。高雄激素型PCOS的妊娠率(29.9% vs 40.2%,P=.02)和活产率(20.1% vs 33.1%,P=.001)较低,调整BMI后活产比值比仍较低(aOR 0.59,CI 0.40-0.89)。
要点
- 高雄激素型PCOS患者妊娠率29.9%、活产率20.1%,均低于非高雄激素型的40.2%和33.1%。
- 高雄激素型PCOS活产 odds 较低(OR 0.51,CI 0.34-0.76),调整BMI后仍较低(aOR 0.59,CI 0.40-0.89)。
- 两组流产率无显著差异(23.9% vs 32.3%,P=.06)。
核心结论
- 高雄激素型PCOS参与者的妊娠率和活产率低于非高雄激素型PCOS参与者。
- 评估不同PCOS表型可能有助于对妊娠和活产概率进行个体化指导。
研究设计与样本
- 回顾性队列研究,纳入PPCOS I和II随机对照试验的参与者,所有参与者均符合美国国立卫生研究院(NIH)的PCOS诊断标准。
- 根据医学访谈、人口学资料、体格检查和实验室数据,将参与者分为四个鹿特丹标准类别中的三个。
- 比较两个高雄激素型(A和B)鹿特丹类别与非高雄激素型PCOS(表型D)。
- 共纳入1376例参与者,其中1249例(90.8%)为高雄激素型PCOS,127例(9.2%)为非高雄激素型PCOS。
主要发现
- 高雄激素型PCOS与非高雄激素型PCOS相比,BMI较高(35.5±8.9 vs 31.9±9.3 kg/m²,P<.001),空腹胰岛素较高(21.6±27.7 vs 14.7±15.0 micro-international units/mL,P<.001),稳态模型胰岛素抵抗评分较高(5.01±9.1 vs 3.4±4.1,P=.0002)。
- 两组年龄和种族相似;高雄激素型PCOS尝试妊娠月数较多(41.8±37.3 vs 33.9±32.0)。
- 高雄激素型PCOS妊娠率较低(29.9% vs 40.2%,P=.02),活产率较低(20.1% vs 33.1%,P=.001)。
- 两组流产率无显著差异(23.9% vs 32.3%,P=.06)。
- 高雄激素型PCOS活产 odds 较低(OR 0.51,CI 0.34-0.76),调整BMI后仍较低(aOR 0.59,CI 0.40-0.89);妊娠 odds 较低(OR 0.63,CI 0.44-0.92),调整BMI后不再显著(aOR 0.74,CI 0.50-1.10)。
关键数值与推荐
- 高雄激素型PCOS活产 OR 0.51(CI 0.34-0.76),调整BMI后 aOR 0.59(CI 0.40-0.89)。
- 高雄激素型PCOS妊娠 OR 0.63(CI 0.44-0.92),调整BMI后 aOR 0.74(CI 0.50-1.10)。
- 妊娠率高雄激素型29.9% vs 非高雄激素型40.2%(P=.02);活产率20.1% vs 33.1%(P=.001);流产率23.9% vs 32.3%(P=.06)。
临床怎么用
- 评估不同PCOS表型可能有助于对妊娠和活产概率进行个体化指导。
- 产前并发症和新生儿结局的总体发生率低,无法进行有意义的比较。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare pregnancy and neonatal outcomes in women with hyperandrogenic polycystic ovarian syndrome (PCOS) phenotypes compared with nonhyperandrogenic PCOS phenotypes. METHODS: We conducted a retrospective cohort study of participants in the PPCOS (Pregnancy in Polycystic Ovary Syndrome) I and II randomized controlled trials; all of the participants met the National Institutes of Health diagnostic criteria for PCOS and were then sorted into three of the four Rotterdam criteria categories based on medical interview, demographics, physical examination, and laboratory data. The two hyperandrogenic (A and B) Rotterdam categories were compared with the nonhyperandrogenic phenotype of PCOS (phenotype D). Our outcomes of interest were clinical pregnancy, pregnancy loss, live birth, obstetric complications (including preterm labor, preeclampsia, gestational diabetes, intrauterine growth restriction, and premature rupture of membranes), and neonatal outcomes (including jaundice, respiratory distress syndrome, neonatal hospitalization, and neonatal infection). RESULTS: Of the 1,376 participants included in the study, 1,249 (90.8%) had hyperandrogenic PCOS phenotypes compared with 127 (9.2%) nonhyperandrogenic PCOS (nonhyperandrogenic PCOS). Compared with participants with nonhyperandrogenic PCOS, those with hyperandrogenic PCOS had higher body mass index (BMI) (35.5±8.9 vs 31.9±9.3 kg/m 2 , P <.001), fasting insulin (21.6±27.7 vs 14.7±15.0 micro-international units/mL, P <.001), and homeostatic model assessment for insulin resistance score (5.01±9.1 vs 3.4±4.1, P =.0002). Age and race were similar between groups. Months attempting pregnancy were greater in participants with hyperandrogenic PCOS compared with nonhyperandrogenic PCOS (41.8±37.3 vs 33.9±32.0). The proportion of participants who achieved pregnancy (29.9% vs 40.2%, P =.02) and live birth rates (20.1% vs 33.1%, P =.001) were lower among those with hyperandrogenic PCOS compared with nonhyperandrogenic PCOS, although pregnancy loss rates did not differ significantly (23.9% vs 32.3%, P =.06). The hyperandrogenic PCOS group had lower odds of live birth compared with the nonhyperandrogenic PCOS group (odds ratio [OR] 0.51, CI, 0.34-0.76), even after adjusting for BMI (adjusted odds ratio [aOR] 0.59, CI, 0.40-0.89). The hyperandrogenic PCOS group also had lower odds of achieving pregnancy compared with the nonhyperandrogenic PCOS group (OR 0.63, CI, 0.44-0.92); however, this association was no longer significant after adjusting for BMI (aOR 0.74, CI, 0.50-1.10). The overall low prevalence of prenatal complications and neonatal outcomes precluded a meaningful comparison between the two groups. CONCLUSION: Participants with hyperandrogenic PCOS achieved lower rates of pregnancy and live birth compared with those with nonhyperandrogenic PCOS. Evaluating distinct PCOS phenotypes may allow for individualized guidance regarding the probability of pregnancy and live birth. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov , NCT00068861 and NCT00718186.
引用
- Chan JL, Legro RS, Eisenberg E, et al. Correlation of Polycystic Ovarian Syndrome Phenotypes With Pregnancy and Neonatal Outcomes. Obstet Gynecol. 2024. PMID: 39173182. doi:10.1097/AOG.0000000000005702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。